

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for ~~systemic modulation of an inflammatory reaction~~ inhibiting the recruitment and the activation of neutrophils in an individual in need, said method comprising ~~administrating~~ administering to said individual an ~~effective amount of chemotactic factor inhibitor, said chemotactic factor being selected from the group consisting of an S100 protein, a protein of the MRP family, calprotectin, and calgranulin~~ antibody against a S100A8 or S100A9 protein, thereby inhibiting the recruitment and the activation of said neutrophils of said individual.
2. (Cancelled)
3. (Currently amended) The method of claim 1, wherein said recruitment and said activation of neutrophils is associated with an inflammatory reaction ~~is~~ selected from the group consisting of arthritis, chronic polyarthritis, rheumatoid arthritis, gout, asthma, psoriasis, ~~paraneoplastic syndrome,~~ tumor-induced inflammatory diseases, ~~turbid effusions, collagenosis,~~ postinfectious arthritis, seronegative spondylarthritis, vasculitis, sarcoidosis, arthrosis, ~~cell chemotaxis, cell migration, cell recruitment, proteolysis, oxidative burst, and radical oxidation~~ and graft rejection.
4. (Cancelled)
5. (Currently amended) The method of claim 1, wherein said administration is ~~performed~~ by selected from the group consisting of intravenous, oral, intranasal, subcutaneous, topically, ~~or~~ and intraperitoneal administration.

6. (Original) The method of claim 1, wherein said individual is a human or an animal.
7. (Original) The method of claim 6, wherein said animal is a mammal.
8. to 11. (Cancelled)
12. (Currently amended) A composition for ~~modulating an inflammatory reaction comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a chemotactic factor inhibitor selected from the group consisting of an S100 protein, a protein of the MRP family, calprotectin, and calgranulin~~ inhibiting the recruitment or the activation of neutrophils in an individual in need, said composition comprising an antibody against a S100A8 or S100A9 protein and a pharmaceutically acceptable carrier.
13. (Cancelled)